Mirdametinib Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 1 mg, 2mg
Reference Brands: Gomekli (USA), Ezmekly (EU/UK)
Category: Oncology Cancer Care
Mirdametinib is an orally administered small-molecule inhibitor of MEK1 and MEK2 (part of the RAS/RAF/MEK/ERK signalling pathway). It is indicated for the treatment of patients (2 years and older) with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that cannot be completely removed by surgery. Mirdametinib is available in Capsules and strengths such as 1 mg, 2mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Mirdametinib is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Mirdametinib can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Mirdametinib is used for the treatment of adults and children aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas. It helps shrink tumor size and relieve symptoms such as pain and functional impairment.
Mirdametinib is made from the active compound mirdametinib, a synthetic small-molecule inhibitor of MEK1 and MEK2 enzymes, which are part of the MAPK signaling pathway involved in cell growth and differentiation.
The trade name of Mirdametinib is Gomekli.
Mirdametinib is manufactured by SpringWorks Therapeutics, Inc.
The generic name of this product is Mirdametinib.
The brand name is Gomekli.
Mirdametinib is manufactured in the United States by SpringWorks Therapeutics under approved regulatory standards.
Related Products
Momelotinib
Strength:
100 mg, 150 mg, 200 mg
Form: Tablets
Reference Brands: Ojjaara (USA)
View Details
Nirogacestat
Strength:
50 mg
Form: Tablets
Reference Brands: Generic formulations marketed under different names
View Details
Nintedanib
Strength:
100 mg, 150 mg
Form: Capsules
Reference Brands: Ofev (USA, EU), Vargatef (EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
